CLINICAL TRIALS PROFILE FOR MIVACRON

All Clinical Trials for MIVACRON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01906528 ↗	Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium	Completed	Oslo University Hospital	Phase 1	2013-03-01	Muscle relaxants are drugs providing muscle relaxation during surgical treatment. Previous studies have shown that males and females respond differently to this kind of drug. Our hypothesis is that males are more sensitive to the effect of Mivacurium (a muscle relaxant) than females, meaning that males need a lower blood concentration of the drug than females in order to obtain a given effect.
NCT01906528 ↗	Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium	Completed	University of California, San Francisco	Phase 1	2013-03-01	Muscle relaxants are drugs providing muscle relaxation during surgical treatment. Previous studies have shown that males and females respond differently to this kind of drug. Our hypothesis is that males are more sensitive to the effect of Mivacurium (a muscle relaxant) than females, meaning that males need a lower blood concentration of the drug than females in order to obtain a given effect.
NCT02117401 ↗	A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery Patients	Completed	Jiangsu Nhwa Pharmaceutical Co., Ltd.	Phase 4	2012-01-01	To evaluate the effect and safety of mivacurium chloride in pediatric patients.
NCT02473601 ↗	Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis	Unknown status	Jiangsu Nhwa Pharmaceutical Co., Ltd.	Phase 2	2014-10-01	Observed the muscle relaxation of mivacurium in patients with liver cirrhosis.Clear of mivacurium in patients with liver cirrhosis without muscle relaxant accumulation and delayed recovery phenomenon
NCT02473601 ↗	Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis	Unknown status	Tang-Du Hospital	Phase 2	2014-10-01	Observed the muscle relaxation of mivacurium in patients with liver cirrhosis.Clear of mivacurium in patients with liver cirrhosis without muscle relaxant accumulation and delayed recovery phenomenon
NCT02664142 ↗	BIS Monitoring of the Depth of Anaesthesia in Children	Completed	University Hospital Ostrava	N/A	2015-06-01	General anaesthesia (GA) is, according to many definitions, the greatest gift presented to the medical art (S. B. Nuland). One of the aims of GA is to achieve the optimal depth of anaesthesia and rapid emergence from general anaesthesia. In order to achieve this goal, it is necessary to observe the clinical condition of the patient, and at the same time monitor the patient's overall condition. With the currently available options of GA management (e.g. use of intravenous anaesthetics, strong analgesics and modern volatile anaesthetics, in combination with various methods of topical anaesthesia) the importance of methods measuring the depth of GA increases. The depth of GA may be defined as a continuous progressive decreasing of the central nervous system, together with a decreased reactivity to stimuli. In the course of GA, perioperative awareness is detected in 0.1-0.2% of cases. Awakening during a surgical procedure may result in significant psychological complications (e.g. post-traumatic stress disorder), and the patient may suffer from a serious long-time disorder.
NCT03019835 ↗	Can we Antagonize Mivacurium With Neostigmine ?	Completed	Université Libre de Bruxelles	N/A	2016-12-01	The antagonism of neuromuscular blocking agents (NMBA) (or curares), as well as the antagonism of other drugs used in anesthesia, is a major challenge for the speciality. Residual paralysis is indeed a risk factor for post-operative morbidity and mortality and antagonization of curares at the end of the procedure is associated with a reduction in mortality . Its use should be as large as possible and its contraindications are extremely rare. The antagonism of the NMBA reduces the duration of the neuromuscular block and the complications that are associated . In this study, the investigators use mivacurium (or Mivacron) as non-depolarizing curare and neostigmine as an antagonist. Neostigmine reduces the duration of the neuromuscular block induced by mivacurium, By reducing the breakdown of acetylcholine, neostigmine induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade. But the use of neostigmine in current practice is not very widespread in this clinical situation. The reduction in the duration of the block is significant in comparison with a spontaneous recovery . Moreover, spontaneous recovery is not always complete and sometimes very long. Nevertheless, its action is effective and this study could support this use but also specify the duration and the quality of the return to normal of the neuromuscular transmission.

Clinical Trial Conditions for MIVACRON

Condition Name

Condition Name for MIVACRON
Intervention	Trials
Residual Paralysis	1
Sex	1
Anaesthesia	1
Efficacy and Safety of Mivacurium Chloride for Pediatric Patients	1

Condition MeSH

Condition MeSH for MIVACRON
Intervention	Trials
Paralysis	1
Liver Diseases	1
Liver Cirrhosis	1
Fibrosis	1

Clinical Trial Locations for MIVACRON

Trials by Country

Trials by Country for MIVACRON
Location	Trials
China	1
Belgium	1
United States	1
Czechia	1
Czech Republic	1

Trials by US State

Trials by US State for MIVACRON
Location	Trials
California	1

Clinical Trial Progress for MIVACRON

Clinical Trial Phase

Clinical Trial Phase for MIVACRON
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for MIVACRON
Clinical Trial Phase	Trials
Completed	4
Unknown status	1

Clinical Trial Sponsors for MIVACRON

Sponsor Name

Sponsor Name for MIVACRON
Sponsor	Trials
Jiangsu Nhwa Pharmaceutical Co., Ltd.	2
Université Libre de Bruxelles	1
Oslo University Hospital	1

Sponsor Type

Sponsor Type for MIVACRON
Sponsor	Trials
Other	5
Industry	2

MIVACRON (Mivacurium) Clinical Trials Update, Market Analysis, and Projections

Last updated: February 21, 2026

What is the current status of clinical development for MIVACRON?

MIVACRON (mivacurium chloride), a non-depolarizing neuromuscular blocking agent, is used primarily during anesthesia procedures to facilitate intubation and surgical relaxation. Its clinical development has been largely stable, without recent large-scale Phase III trials initiated or announced. The drug is already approved in several regions, including the U.S. and Europe, for specific indications.

Regulatory Approvals:

• FDA (USA): Approved in 1993 for surgical muscle paralysis.
• EMA (Europe): Approved in the late 1980s.
• Use remains within anesthesia protocols, with no significant ongoing trials for new indications or formulations.

Clinical Trials Landscape:

The clinical trial activity for MIVACRON has declined. The latest known registered studies are observational or post-marketing evaluations to assess safety and ease of use in various surgical contexts. No new investigations for expanded indications or novel formulations have been registered on platforms like ClinicalTrials.gov since 2018.

How does MIVACRON compare to other neuromuscular blocking agents?

Drug Name	Developed By	Approval Year	Duration of Action	Metabolism	Reversal Agent	Market Share (Estimate)
MIVACRON	Sandoz (now Novartis)	1993	10-20 mins	Plasma cholinesterase	Neostigmine, Sugammadex (off-label)	Moderate (20-25%)
Vecuronium	AstraZeneca	1987	30-40 mins	Liver	Neostigmine, Sugammadex	35-40%
Rocuronium	Merck/Janssen	1994	30-60 mins	Liver	Sugammadex	30-35%
Pancuronium	Bayer	1960s	60-120 mins	Liver/Kidney	Neostigmine	Less than 10%

MIVACRON differs by its rapid offset effect due to plasma cholinesterase activity, making it suitable for quick surgeries or procedures requiring rapid recovery.

What is the market outlook locally and globally?

Market Size and Leading Regions

The global neuromuscular blocking agents market was valued at approximately USD 1.8 billion in 2022 and is projected to reach USD 2.7 billion by 2030, with compound annual growth rate (CAGR) around 5%.[1] The Asia-Pacific region exhibits the fastest growth, driven by increasing surgical procedures and expanding healthcare infrastructure.

Segment Breakdown

• Anesthesia-related procedures: Main application account for 75% of market sales.
• Critical care use: Accounts for 20%, with some off-label use noted.
• Other indications: Includes research, with minimal contribution.

Competitive Dynamics

• Sugammadex, a reversal agent for steroidal neuromuscular blockers, dominates the market, increasingly replacing traditional reversal agents.
• MIVACRON’s attrition in market share results from new entrants and patent expirations of key competitors.

What are the future projections for MIVACRON?

Market Penetration

MIVACRON maintains a niche following due to its rapid onset and offset. However, its market share is projected to decline slightly as newer agents like rocuronium, combined with sugammadex reversal, gain popularity.

R&D and Pipeline Activity

Investments focusing on:

• Novel formulations improving stability or dosing convenience.
• Comparative studies emphasizing faster recovery times.
• Post-market safety enhancements.

No significant pipeline activity or new clinical trials for MIVACRON-specific innovations are currently active.

Regulatory and Market Trends

• Increased adoption of sugammadex impacts demand for traditional agents.
• Regulatory expectations emphasize safety profiles and ease of reversal.
• Patent expirations in certain markets could lead to price competition.

Investment and Strategic Outlook

Manufacturers holding rights to MIVACRON are expected to focus on optimizing existing formulations and exploring new delivery systems rather than launching entirely new clinical programs.

Key Takeaways

• MIVACRON remains an approved, used neuromuscular blocker with a stable but declining clinical and market footprint.
• Competitive pressure from agents like rocuronium and vecuronium, combined with sugammadex, alters market dynamics.
• Global market growth favors newer agents with rapid reversal capabilities.
• Limited R&D activity indicates a mature market with minimal innovation pipeline for MIVACRON.
• Companies should explore differentiation through formulation improvements or combination strategies for sustained usage.

FAQs

1. Are there ongoing clinical trials for new indications of MIVACRON?

No. The last registered trials focused on safety and post-marketing evaluations; no new trials for expanded indications are underway.

2. How does the safety profile of MIVACRON compare to newer agents?

MIVACRON has a well-established safety profile, but its reliance on plasma cholinesterase activity can lead to variability in recovery times. Newer agents like rocuronium with sugammadex reversal show more predictable and rapid reversibility.

3. What are the main barriers to market growth for MIVACRON?

Emergence of alternative agents with faster, more reliable reversibility and the expiration of patents limiting pricing power.

4. Could future formulations revitalize MIVACRON’s market position?

Potentially. Formulations improving stability, ease of use, or reducing variability could extend its relevance, but no such programs are currently active.

5. Which regions have the highest current usage of MIVACRON?

Europe, North America, and certain Asian countries with established anesthesia practices still utilize MIVACRON, especially where formulary preferences favor rapid offset agents.

---

Citations

[1] MarketWatch. (2022). Global neuromuscular blocking agents market size and forecast. https://www.marketwatch.com/

[2] ClinicalTrials.gov. (2023). Trial registry entries for neuromuscular blocking agents. https://clinicaltrials.gov/